AstraZeneca Casodex review
Executive Summary
FDA's Oncologic Drugs Advisory Committee Dec. 18 meeting on AstraZeneca's supplemental NDA for Casodex in non-metastatic prostate cancer will be at the Holiday Inn in Bethesda, Md., beginning at 8 a.m. The company is expected to discuss differences in results of U.S. and international trials...